Similar articles

• Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.

  West WH. West WH. Immunol Ser. 1989;48:79-92. Immunol Ser. 1989. PMID: 2488327 Clinical Trial. No abstract available.
• Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.

  Clark J, Longo DL. Clark J, et al. Immunol Ser. 1989;48:37-58. Immunol Ser. 1989. PMID: 2488325 Clinical Trial. No abstract available.
• Therapy with interleukin-2 and tumor-derived activated lymphocytes.

  Oldham RK. Oldham RK. Immunol Ser. 1994;61:251-71. Immunol Ser. 1994. PMID: 8011748 Review. No abstract available.
• Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.

  Blacklock JB, Grimm EA. Blacklock JB, et al. Immunol Ser. 1989;48:93-9. Immunol Ser. 1989. PMID: 2488328 No abstract available.
• [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].

  Barón Saura JM, Pizarro Redondo A, Berrocal Jaime A, González Barón M. Barón Saura JM, et al. Rev Clin Esp. 1991 May;188(9):468-72. Rev Clin Esp. 1991. PMID: 1896596 Review. Spanish.